“Only 30.95 per cent of commercially available CBD products are accurately labelled.” — Journal of the American Medical Association

The federal government is about to subsidise a product that fails basic quality tests nearly 70 per cent of the time. Officials have quietly finalised CBD Medicare coverage, and they will soon make a public announcement. The most medically vulnerable Americans in the country will receive these products. Nobody voted on this. Nobody debated it. The cannabis industry already knows. You probably do not.

How CBD Medicare Coverage Got Approved Without You Noticing

In December 2024, the Trump administration signed an executive order directing the rescheduling of marijuana from Schedule I to Schedule III. That made headlines. What did not draw attention was a separate initiative that the Centers for Medicare and Medicaid Services announced the same day: a pilot programme that places hemp-derived CBD products inside the federal health insurance system.

CMS Administrator Mehmet Oz stood at the signing ceremony and outlined the plan. Doctors would be able to recommend CBD for Medicare patients managing chronic pain, including cancer-related pain, at no cost to the patient. Officials were asking Medicare Advantage insurers that cover 34 million Americans to follow suit. It is worth noting who is making that ask: the same person who said in 2020 that cannabis is “one of the most underused tools in America” and argued it should replace narcotics for seniors managing pain. Oz is not a neutral regulator on this question.

Then in February 2026, Jared Stanley, co-founder of Charlotte’s Web, one of America’s largest hemp companies, told a cannabis industry webinar that officials had internally finalised the rulemaking roughly two weeks earlier. He said they expected an announcement ahead of the April launch. Stanley also made it clear that the programme would not remain contained. Officials plan to expand it well beyond the initial pilot into multiple indications.

For the cannabis industry, this marks a landmark moment. For everyone else, there has been silence.

What the FDA Actually Knows About CBD

The only CBD product the FDA has fully approved is Epidiolex, a pharmaceutical-grade formulation prescribed for two specific rare seizure disorders, used under strict medical supervision. Manufacturers sell every other CBD product on the market without approval, without independent verification, and without meeting any federally mandated safety standard whatsoever.

This is not a fringe position. It is the FDA’s own. Americans Against Legalizing Marijuana (AALM) is one of the few organisations in the country willing to say it plainly and on the record. A national coalition of doctors, lawyers, educators, parents and community advocates, AALM has formally challenged the CBD Medicare coverage push by submitting a detailed research paper directly to HHS Secretary Kennedy and FDA Commissioner Dr Martin Makary, demanding enforcement of existing food and drug laws before the rollout proceeds. Their documentation of CBD’s known risks, drawn entirely from FDA and peer-reviewed sources, is available at aalm.info and makes for essential reading for anyone following this issue.

Even Epidiolex, the regulated version, carries serious FDA-mandated warnings: liver injury, sedation, suicidal ideation, hypersensitivity reactions, and dangerous interactions with anti-epilepsy drugs. Clinical trials for Epidiolex did not include a single patient over 55. The CBD Medicare coverage pilot is aimed squarely at patients aged 65 and over.

Seven Out of Ten Products Fail Basic Labelling Standards

That JAMA figure is not an outlier. It sits inside a consistent body of evidence showing the commercial CBD market cannot reliably deliver what it claims to sell.

An FDA marketplace sampling study tested 102 CBD products that specified a CBD amount. Eighteen per cent contained less than 80 per cent of the stated dose. Thirty-seven per cent contained more than 120 per cent. Nearly half contained detectable THC. A National Institutes of Health study found THC present in 21 per cent of online products at concentrations sufficient, the study noted, to intoxicate children.

Beyond mislabelling, contamination is a documented and serious problem. Testing has found heavy metals including lead, copper and nickel, alongside pesticides, bacteria, mould and fungus. One nationally recalled product caused acute lead poisoning, and patients reported neurological toxicity, kidney damage, and encephalitis. Federal health authorities are now integrating CBD coverage into this very market.

A truck driver lost his job after he tested positive for THC following CBD use, even though the manufacturer told him the product contained none. He sued under RICO. The US Supreme Court confirmed in Medical Marijuana v. Horn (2025) that such lawsuits can proceed. The legal framework is still catching up to a market that has been running well ahead of it.

There is also a collision no one in the policy discussion is acknowledging. The Department of Transportation has issued a formal notice warning that CBD use can produce a positive THC result on a drug test, and that CBD is not a legitimate medical explanation for a confirmed positive. A Medicare patient recommended CBD by their doctor under this federal programme could take it faithfully, then lose their job because a workplace drug test cannot distinguish between the two. The federal government would have created that outcome.

The Patients Who Cannot Afford to Be Guinea Pigs

Older adults are not a low-risk population for CBD. They are the highest-risk one.

CBD inhibits liver enzymes responsible for metabolising a wide range of drugs. For a Medicare patient managing heart disease, diabetes, cancer or post-transplant immunosuppression, the interaction risk is not theoretical. Peer-reviewed case reports have documented warfarin interactions. Researchers have also established interactions with immunosuppressive chemotherapy drugs. The FDA has stated explicitly that CBD for elderly persons carries elevated danger given the frequency of decreased liver and cardiac function in this age group.

CBD also raises intra-ocular pressure, the primary driver of glaucoma and a leading cause of blindness. The American Academy of Ophthalmology does not recommend cannabis for glaucoma or any other eye condition. Officials are about to recommend this compound to patients even though doctors may have no reliable way to verify the actual dose or identify contaminants in the products they prescribe.

Someone Will Answer For This

The cannabis industry’s argument that prohibition blocked research is legitimate. But the answer to a research gap is research, not a federal rollout.If CBD genuinely helps elderly patients manage pain, prove it the way every other medicine earns approval: conduct proper trials, publish the data, submit it to peer review, and secure regulatory approval. The people pushing these shortcuts are not acting out of compassion. They are convenient for an industry that has spent years trying to get its products into the healthcare system without clearing the bar every other product must clear.

This rollout can still be challenged. The FDA has the authority to act. So do the FTC, the DEA and HHS. AALM has been building the evidentiary case for exactly this moment, and their work gives the public, policymakers and journalists the tools to push back. If this issue matters to you, aalm.info is where the fight is being organised. The question is whether enough people find out before April, or whether this becomes one of those policies everyone discovers only after it is already running.

Patients who enrol in this programme will not have the luxury of discovering later that the product did not contain what it claimed.

Source: Marijuana Moment